Table 1. Overview of all payments received by health related APPGs between 2012–2018.
| APPG name | Payments from all external sources | Payments from pharmaceutical companies and pharmaceutical industry-funded patient organisations | ||||
|---|---|---|---|---|---|---|
| Value of payments—£ | Number of payments—n§ | Number of payments with value—n (%) | Value of payments—£ (%)¶ | Number of payments—n (%)¶ | Number of payments with value—n (%)¶ | |
| Cancer‡ | 442,318.21 | 54 | 50 | 440,573.21 (99.61) | 53 (98.15) | 49 (98) |
| Health* | 1,017,516.98 | 108 | 104 | 414,921.47 (40.78) | 47 (43.52) | 47 (45.19) |
| Thrombosis‡ | 224,094.40 | 9 | 5 | 146,545.81 (65.39) | 8 (8.89) | 4 (80) |
| Sickle Cell and Thalassaemia* | 122,527.46 | 16 | 8 | 122,527.46 (100) | 16 (100) | 8 (100) |
| Sepsis† | 154,979.29 | 11 | 8 | 71,441.14 (46.10) | 3 (27.27) | 3 (37.50) |
| HIV and AIDS* | 329,525.96 | 42 | 41 | 66,083.63 (20.05) | 7 (16.67) | 7 (17.07) |
| Rare, Genetic and Undiagnosed Conditions† | 65,595.93 | 4 | 4 | 65,595.93 (100) | 4 (100) | 4 (100) |
| Dementia† | 64,296.82 | 17 | 13 | 64,296.82 (100) | 17 (100) | 13 (100) |
| Liver Health‡ | 59,906.00 | 10 | 6 | 59,906.00 (100) | 10 (100)* | 6 (100) |
| Obesity* | 94,763.94 | 7 | 3 | 45,531.23 (48.05) | 1 (14.29) | 1 (33.33) |
| Autism† | 45,065.61 | 8 | 4 | 45,065.61 (100) | 8 (100) | 4 (100) |
| Atrial Fibrillation‡ | 51,935.62 | 8 | 4 | 46,297.69 (89.14) | 8 (100) | 4 (100) |
| Alcohol Harm‡ | 51,264.61 | 8 | 4 | 40,014.11 (78.05) | 8 (100) | 3 (75) |
| Sexual and Reproductive Health‡ | 115,768.08 | 16 | 11 | 37,961.99 (32.79) | 8 (10) | 4 (36.36) |
| Women’s Health* | 71,223.12 | 3 | 3 | 35,611.56 (50) | 8 (100) | 3 (100) |
| Breast Cancer† | 34,058.30 | 10 | 6 | 34,058.3 (100) | 10 (100) | 6 (100) |
| Pancreatic Cancer† | 33,935.61 | 8 | 4 | 33,935.61 (100) | 8 (100) | 4 (100) |
| Eye Health and Visual Impairment‡ | 32,250.50 | 9 | 1 | 32,250.50 (100) | 5 (55.56) | 1 (100) |
| Brain Tumours† | 46,494.61 | 10 | 4 | 30,997.96 (66.67) | 10 (100) | 4 (100) |
| Multiple Sclerosis† | 29,344.54 | 12 | 4 | 29,344.54 (100) | 12 (100) | 4 (100) |
| Baby Loss† | 29,114.20 | 4 | 4 | 29,114.2 (100) | 4 (100) | 4 (100) |
| Stem Cell Transplantation† | 26,552.76 | 10 | 6 | 26,552.76 (100) | 10 (100) | 6 (100) |
| Skin* | 222,779.70 | 27 | 23 | 23,437.37 (10.52) | 13 (48.15) | 13 (56.52) |
| Ageing and Older People† | 21,698.59 | 8 | 4 | 21,698.59 (100) | 8 (100) | 4 (100) |
| Diabetes‡ | 20,575.70 | 11 | 7 | 20,575.70 (100) | 11 (100) | 7 (100) |
| Muscular Dystrophy† | 19,250.08 | 9 | 5 | 19,250.08 (100) | 9 (100) | 5 (100) |
| Tuberculosis* | 58,650.74 | 19 | 9 | 19,114.06 (32.59) | 5 (26.32) | 4 (44.44) |
| Haemophilia and Contaminated Blood† | 17,168.74 | 10 | 6 | 17,168.74 (100) | 10 (100) | 6 (100) |
| Osteoporosis† | 16,188.16 | 10 | 3 | 16,188.16 (100) | 10 (100) | 3 (100) |
| Young Disabled People† | 15,499.58 | 8 | 4 | 15,499.58 (100) | 4 (50) | 4 (100) |
| Motor Neurone Disease† | 10,693.15 | 8 | 4 | 10,693.15 (100) | 8 (100) | 4 (100) |
| Heart and Circulatory Diseases† | 10,063.56 | 7 | 3 | 10,063.56 (100) | 4 (57.14) | 3 (100) |
| Ovarian Cancer† | 9,300.58 | 8 | 4 | 9,300.58 (100) | 8 (100) | 4 (100) |
| Children, Teenagers, and Young Adults with Cancer† | 9,106.27 | 4 | 4 | 9,106.27 (100) | 4 (100) | 4 (100) |
| Blood Cancer† | 8,489.30 | 3 | 3 | 8,489.3 (100) | 3 (100) | 3 (100) |
| Malaria and Neglected Tropical Diseases* | 270,418.00 | 35 | 32 | 8,250.50 (3.05) | 1 (2.86) | 1 (3.13) |
| 22 other APPGs† | 248,423.16 | 158 | 35 | 69,937.58 (28.15) | 110 (69.62) | 24 (68.57) |
| Total | 4,100,837.87 | 709 | 443 | 2,197,400.75 (53.58) | 468 (66.01) | 278 (62.75) |
* APPGs receiving payments from pharmaceutical companies only (n = 8).
† APPGs receiving payments from pharmaceutical industry-funded patient organisations (n = 42).
‡ APPG receiving payments from both the pharmaceutical industry and pharmaceutical industry-supported patient organisations (n = 8).
§ Four payments were jointly from a pharmaceutical company and a pharmaceutical industry funded patient organisation–these are counted as four payments rather than eight.
¶ Percentages are the number/value of payments from pharmaceutical companies and pharmaceutical industry-funded patient organisations as a proportion of the total number/value of payments received by each APPG.